{"id":"arct-021-dose-regimen-2","_chembl":{"chemblId":"CHEMBL4075278","moleculeType":"Small molecule","molecularWeight":"417.85"},"_dailymed":null,"_scrapedAt":"2026-03-28T04:54:09.965Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123598,"model":"claude-sonnet-4-5-20250929"},"description":"ARCT-021 Dose Regimen 2 is an investigational therapeutic developed by Arcturus Therapeutics, Inc., currently in Phase 1 clinical development. Limited public information is available regarding its molecular target, mechanism of action, or specific therapeutic indication at this early stage of development.","indications":{"approved":[{"status":"investigational","condition":null,"patientPopulation":null}]},"trialDetails":[{"nctId":"NCT04480957","phase":"PHASE1, PHASE2","title":"Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2020-08-04","conditions":"SARS-CoV-2","enrollment":106}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"ARCT-021 Dose Regimen 2","genericName":"ARCT-021 Dose Regimen 2","companyName":"Arcturus Therapeutics, Inc.","companyId":"arcturus-therapeutics-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":1,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}